TABLE IV.
Association of ITPA With Treatment Response (RVR, EVR, and SVR) in Patients Coinfected With HIV and HCV
| RVR | EVR | SVR | ||||
|---|---|---|---|---|---|---|
| Baseline characteristics | Odds ratio | P-value | Odds ratio | P-value | Odds ratio | P-value |
| [A] Association of the response with baseline characteristics based on univariate logistic regression | ||||||
| ITPA deficiency | 4.952 | 0.012 | 0.823 | 0.748 | 2.776 | 0.093 |
| Age | 0.959 | 0.276 | 0.973 | 0.436 | 0.936 | 0.076 |
| Gender | 0.684 | 0.569 | 1.032 | 0.96 | 1.384 | 0.617 |
| BMI | 0.991 | 0.661 | 0.988 | 0.4 | 0.976 | 0.607 |
| Baseline HIV VL | 0.791 | 0.578 | 0.989 | 0.974 | 1.764 | 0.113 |
| Baseline HCV VL | 0.28 | 0.003 | 0.8 | 0.508 | 0.783 | 0.463 |
| Baseline Hgb | 1.037 | 0.877 | 1.178 | 0.447 | 1.571 | 0.055 |
| Fibrosis (≥2) | 0.611 | 0.069 | 1.245 | 0.328 | 1.012 | 0.958 |
| Creatine | 4.121 | 0.485 | 8.469 | 0.281 | 5.966 | 0.35 |
| Platelet count | 1 | 0.979 | 0.998 | 0.455 | 0.997 | 0.467 |
| CD4 count | 1.001 | 0.377 | 1 | 0.558 | 1 | 0.571 |
| CD4% | 1.02 | 0.492 | 0.989 | 0.682 | 1.028 | 0.318 |
| AZT use | 3.417 | 0.085 | 88664074 | 0.993 | 3.469 | 0.08 |
| IL28 | 1.231 | 0.745 | 17 | 0.008 | 2 | 0.236 |
| [B] Multivariate logistic regression on the association of ITPA with the responses adjusting for IL28 | ||||||
| ITPA deficiency | 6.358 | 0.006 | 0.881 | 0.851 | 3.383 | 0.054 |
| IL28 | 1.402 | 0.627 | 16.936 | 0.008 | 2.215 | 0.192 |
There was no ribavirin reduction in HIV/HCV coinfected patients.
For RVR, only ITPA and baseline HCV are of significant association.
For EVR, only IL28 is of significant association.
For SVR, no baseline characteristics are of significant association.
After adjusting for IL28, ITPA is still significantly associated with RVR, not significantly associated with EVR, and associated with SVR with marginal significance, that is about the same pattern as the univariate logistic regression results.